Migraine & Headache Devices: Do Cefaly, Nerivio, and TENS Units Actually Work — Or Is the Hype Bigger Than the Data?

⚡ Three Different Devices, Three Different Mechanisms

Cefaly uses external trigeminal nerve stimulation (e-TNS), worn on the forehead via a self-adhesive electrode, delivering precise electrical impulses specifically to the trigeminal nerve — the nerve most directly implicated in migraine pain. It’s available over the counter, without a prescription.

Nerivio works completely differently: it’s worn on the upper arm, not the head, using a mechanism called remote electrical neuromodulation (REN). Rather than directly stimulating a head-related nerve, it delivers electrical stimulation to the arm intended to trigger “conditioned pain modulation” — activating the body’s own descending pain-inhibition pathways. It requires a prescription and is controlled through a smartphone app.

Generic TENS units (transcutaneous electrical nerve stimulation) are a much broader, older category of device sold over the counter for general pain relief — back pain, muscle soreness, arthritis — using electrodes placed near the painful area to block pain signals or trigger endorphin release. They are not migraine-specific devices, and, as covered below, aren’t studied or approved for head placement at all.

🧠 Cefaly: The First FDA-Cleared Device for Migraine Prevention

Cefaly was FDA-approved for migraine prevention in 2014 — a genuine regulatory first for this category. It’s worth being precise about the scope of that original clearance: it covers episodic migraine specifically (patients having frequent attacks, but fewer than 15 headache days per month), not chronic migraine, and a separate later clearance extended the device to acute (in-the-moment) treatment as well.

The trial data. The ACME trial — a double-blind, randomized, sham-controlled study conducted across three U.S. headache centers (106 adults, 2016–2017) — tested Cefaly’s acute treatment mode during an active migraine attack. Results, from the trial’s own primary analysis: mean migraine pain intensity after one hour dropped by 59% in the real-treatment group versus 30% in the sham group (p<0.001), with 32% of real-treatment patients pain-free at 24 hours versus 13% in the sham group. A separate, independently conducted replication study in Japan (100 patients across four headache centers, 12-week prospective trial) found Cefaly’s preventive use significantly reduced migraine days (from a baseline of 8.16 to 6.84 days, p=0.0036) and migraine attacks (5.33 to 3.94, p=0.0002), with a 90% compliance rate and only 3% of participants dropping out due to side effects. A 2026 independent review published via PubMed described the overall evidence as “moderate in quality” but real, showing genuine efficacy in reducing migraine frequency, attack pain, and acute medication use across diverse populations.

📱 Nerivio: Broader FDA Clearance, Industry-Funded Trial Base

Nerivio holds a broader FDA clearance than Cefaly in one respect: it’s cleared for both acute and preventive treatment of migraine (with or without aura) in people 12 and older, from the outset. Its pivotal randomized trial for prevention (NCT04828707) was a genuinely rigorous design — prospective, randomized, triple-masked, and sham-controlled, which is about as strong a trial design as this category produces. A separate post-marketing, real-world observational study followed Nerivio users over six months to assess real-world safety, efficacy, and health outcomes.

⚖️ The Independent Pushback Worth Taking Seriously

This is the section that separates a genuinely honest treatment of this topic from simply repeating company-favorable trial summaries, and it’s worth including in full.

An independent healthcare technology assessment (CTAF, a formal evidence-review panel) evaluated Cefaly specifically and reached a notably more skeptical conclusion than the company’s own materials: “only one small trial has been reported of a TENS device (Cefaly) for the prevention of frequent migraine headaches,” further limited by “concerns about unblinding and incomplete reporting of adverse effects.” The panel’s cost-effectiveness modeling, comparing Cefaly against a commonly used generic oral migraine medication, suggested lower overall benefit and higher cost. The panel’s formal conclusion: the evidence is inadequate to demonstrate that Cefaly is as effective as other currently available care options.

Named headache specialists have voiced similar uncertainty directly. Dr. Alexander Mauskop, a headache specialist, has stated plainly: “My patients haven’t had much success with Cefaly. To save them money, I suggest that they try a regular TENS unit, which can cost as little as $50,” while acknowledging he remains genuinely unsure whether Cefaly holds any real advantage over a standard, far cheaper TENS unit. Separately, another headache specialist writing for the American Academy of Neurology’s Neurology Today stated that “regular” TENS units should not be used in place of Cefaly, without fully explaining the specific reasoning — leaving genuine, unresolved disagreement even among specialists in the field about how meaningfully different these device categories actually are in practice.

🚫 Why Manufacturers Say Not to Use Regular TENS on Your Head

Cefaly’s own guidance is direct on this point: standard TENS units, sold for general body pain, should not be used on the head, with e-TNS (Cefaly’s specific, purpose-engineered variant) presented as the only device the company considers safe and appropriate for head placement. It’s worth noting this guidance comes from a company that also sells the specific alternative it’s recommending — a real conflict of interest worth factoring in, even though head placement of unstudied electrical stimulation devices is a reasonable general caution on its own safety-first merits, separate from any commercial motivation. What’s genuinely true, and independent of any single company’s interest, is that generic TENS units are not FDA-cleared or clinically studied specifically for migraine the way Cefaly and Nerivio are — meaning even setting aside the head-placement safety question, using a generic device for migraine specifically means relying on a completely different, largely absent evidence base compared to the two purpose-built devices covered above.

⚠️ Real Safety Considerations

Cefaly’s clinical studies report no serious adverse effects, with minor, reversible effects including sleepiness, post-session headache, forehead redness, nausea, or skin irritation. Both Cefaly and Nerivio carry real contraindications worth knowing: neither should be used by people with metallic or electronic implants in the relevant treatment area, cardiac pacemakers, or implanted/wearable defibrillators, and neither is intended for pain of unknown origin — meaning an actual migraine diagnosis, not just head pain generally, should be established first. Anyone pregnant, breastfeeding, managing a complex medical history, or experiencing new or unusual symptoms should talk to a healthcare provider before starting either device.

📋 What This Regulatory Precision Actually Means for You

It’s worth drawing together the specific clearance details scattered throughout this article, because they matter for realistic expectations: Cefaly’s original and core clearance covers episodic migraine specifically, not chronic migraine (15+ headache days per month) — though some data suggests patients with more frequent attacks may see comparatively more benefit, this remains an area where the company’s own supporting documentation states that dedicated clinical studies in chronic migraine populations specifically are still needed. Nerivio’s clearance explicitly covers both acute and preventive use from a younger starting age (12+) than Cefaly. Availability also differs: Cefaly is sold over the counter; Nerivio requires a prescription. None of these distinctions are marketing details — they reflect what each device’s actual regulatory review specifically evaluated and covers.

💰 Cost, Insurance, and Where These Devices Fit in the Broader Treatment Landscape

It’s worth knowing these devices don’t exist in isolation — they’re one option within a broader migraine-treatment landscape that includes both older, well-established preventive medications and newer, considerably more expensive options. Cefaly is typically available for a few hundred dollars out of pocket without a prescription, and health insurance coverage has historically been slow and inconsistent for these devices, per independent clinical commentary. This matters directly for the cost-effectiveness conclusion reached by the independent CTAF technology assessment above: its modeling found Cefaly compared unfavorably on a cost basis specifically against cheap, generic, well-established oral preventive medications — not against the newest, most expensive branded treatments, where the comparison might look different. This is also part of why the “mildly effective” framing from independent clinical commentary specifically noted that Cefaly’s effect size, modest as it is, is nonetheless in a similar range to some of the newest and most expensive migraine drug classes (like CGRP inhibitors) and Botox — meaning the honest comparison depends heavily on which specific alternative treatment you’re weighing these devices against, not a single universal verdict.

It’s also worth knowing that Cefaly and Nerivio aren’t the only FDA-cleared neuromodulation devices in this broader category — other cleared options include gammaCore (a vagus nerve stimulator), SAVI Dual, Relivion, and Enso for Migraine, each with its own specific clearance scope (some for acute treatment only, others for prevention, with prescription requirements varying by device). This article focuses on Cefaly and Nerivio specifically because they’re the most established and most directly named in the search behind this piece, but it’s worth knowing the broader device category is larger and still evolving, with new entrants receiving clearance on an ongoing basis — meaning the same evidence-versus-marketing scrutiny applied throughout this article is worth applying to any newer device in this category as it emerges, rather than assuming an FDA clearance alone settles how strong the underlying evidence actually is.

📊 Quick Comparison

✅ Questions to Ask Before Trying a Migraine Device

• Is this a purpose-built, FDA-cleared migraine device (Cefaly, Nerivio), or a generic TENS unit being used off-label for migraine? These have meaningfully different evidence bases specifically for migraine.
• Does the device’s clearance cover episodic or chronic migraine, and acute or preventive use? As shown above, these aren’t universal across every device.
• Have you looked at both the company’s own trial summaries and an independent assessment, like a technology-assessment panel’s review? As shown with the CTAF panel’s more skeptical conclusion, these can diverge meaningfully.
• Do you have a pacemaker, implanted defibrillator, or metallic/electronic implant in the treatment area? This rules out use of these devices entirely, per their own safety guidance.
• Has an actual migraine diagnosis been established, rather than head pain generally? Neither device is intended or studied for pain of unknown origin.

🎯 Who This Is Actually Right For

If you have a diagnosed episodic migraine condition and are looking for a non-pharmacologic option, particularly if you have medication contraindications or want to reduce reliance on acute medication, Cefaly or Nerivio represent real, FDA-cleared, randomized-trial-tested options — with the honest expectation, based on the independent assessments above, of a modest rather than dramatic effect size for many users.

If cost is a major factor and you’re specifically weighing a purpose-built device against a much cheaper generic TENS unit, it’s worth knowing that even headache specialists are genuinely divided on this question — some remain unsure whether the purpose-built devices offer a meaningful advantage, which is a legitimate, expert-level uncertainty rather than a settled answer favoring the pricier option.

If your migraines are chronic (15+ headache days monthly), it’s worth discussing directly with a headache specialist whether either device’s evidence base — built primarily around episodic migraine — genuinely applies to your specific situation, since the core clinical trials behind these clearances were not focused on the chronic migraine population.

❓ Frequently Asked Questions

📚 Sources & References

• Cefaly, “Clinical Studies: Proven Migraine Relief with Cefaly” (ACME trial summary)
• ClinicalTrials.gov, NCT03217968 — “Abortive Treatment of Migraine With the Cefaly Abortive Program Device” (ACME trial protocol and detailed results)
• Yamani, N., et al., “The safety and preventive effects of a supraorbital transcutaneous stimulator in Japanese migraine patients,” independent replication study, PMC
• “A profile on the Cefaly Dual trigeminal neurostimulator for acute and preventive migraine treatment: an overview of its safety and efficacy,” PubMed, 2026
• California Technology Assessment Forum (CTAF), “Controversies in migraine management: a technology assessment: final report”
• Dizziness-and-Balance.com, “Migraine devices — TENS” (independent clinician commentary)
• The Daily Headache, “Regular TENS Unit Instead of Cefaly?” (Dr. Alexander Mauskop and Dr. Brian Plato commentary)
• Neurology Today (American Academy of Neurology), “Is the FDA’s Newly Approved Transcutaneous Electrical Nerve Stimulation Device for Migraine Ready for Primetime?”
• ClinicalTrials.gov, NCT04828707 — Nerivio prevention pivotal trial; NCT05940870 — Nerivio post-marketing observational study; NCT04089761 — terminated adolescent trial
• Cefaly Blog, “Migraine Relief vs. Pain Relief: What’s the Difference Between e-TNS and TENS Devices?”
• Cefaly, “Best FDA-Cleared Migraine Devices for Adults in 2026” (regulatory scope comparison across devices)

Verification notes: The ACME trial’s specific figures were drawn from the trial’s own clinicaltrials.gov protocol documentation. The independent Japanese replication study and the 2026 PubMed review were verified via their PMC/PubMed listings respectively. The CTAF technology assessment panel’s more skeptical conclusion, and the named clinicians’ (Mauskop, Plato) direct commentary, are included specifically to balance the company-sourced trial summaries that dominate most coverage of this topic — this article treats both the positive trial data and the independent skepticism as part of the honest evidentiary picture, rather than presenting only one side. All Nerivio clinical trials identified for this article were sponsored by Theranica, the device’s manufacturer; this is disclosed directly in the text rather than presented as independent research.

💡 The Bottom Line

Cefaly and Nerivio represent genuinely real, FDA-cleared, clinically-trialed migraine technology — a rare category where sham-controlled randomized trials actually exist and show statistically significant results. But “statistically significant” and “dramatically effective” aren’t the same thing, and an independent technology-assessment panel’s conclusion that the evidence is inadequate compared to standard care options, alongside named headache specialists’ genuine uncertainty about any real advantage over a $50 generic TENS unit, deserves equal weight alongside the positive trial summaries these companies (understandably) lead with. Generic TENS units, meanwhile, remain a real, separately-evidenced option for general body pain, but not a validated substitute for migraine-specific treatment, and manufacturer guidance specifically cautions against placing them on the head at all. The honest picture: real evidence, real effect, genuinely modest in size, and genuine, ongoing expert disagreement about whether the premium over cheaper alternatives is actually justified.